The IABP-SHOCK II trial is the largest randomized trial of intra-aortic balloon pump (IABP) counterpulation support in cardiogenic shock. At 30-days follow-up, this trial demonstrated no mortality reduction. The current paper reports the longer term outcomes from this trial, given that the benefits of IABP may not be evident in early follow-up. […]